Ausper Biopharma Co., Ltd.

This phase 2 trial tests an injection called AHB-137 in adults with chronic hepatitis B who have not yet received treatment. The study compares AHB-137 to a placebo to see if it can lower the amount of hepatitis B virus in the blood and reduce a key marker of infection (HBsAg). P…

This Phase 2 trial tests an injection called AHB-171 in 138 people with chronic hepatitis B. The goal is to see if it can lower hepatitis B surface antigen and viral DNA to very low levels, potentially leading to a functional cure. Participants include those who have never been t…

This early-stage study tests a single injection of AHB-137 in 32 people with chronic hepatitis B, some with mild to moderate liver dysfunction and some with normal liver function. Researchers will measure how the drug moves through the body and check for safety issues. The goal i…